Thursday, November 19, 2026

Biotech Keeps Hitting Clinical Milestones While a Tech Selloff Tests the Money Behind It

Scribe, Vor, Akari and BioArctic all reported progress this autumn, and Incyte's SEC-filed cash stood at $3.28 billion. A $1 trillion tech selloff and a cut to OpenAI's funding target show how risk appetite could shape what biotech can raise next.

Via News Editorial Team

November 19, 2026

This article was generated by AI. Built from the source documents listed below. How we work

Source Trace Score12 source documents12 with a live linkVerifiability: Strong
Biotech Keeps Hitting Clinical Milestones While a Tech Selloff Tests the Money Behind It
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

The science is moving, and so is the mood around it

Biotech companies kept reaching clinical milestones through the fourth quarter of 2026. They did so just as a $1 trillion technology selloff on 30 October, the Nasdaq 100's worst day since June, deepened fears of an AI bubble.1 The two stories are linked because AI has become part of how drugs are discovered and delivered, and because biotech's access to money depends on how willing investors are to take risk. Most clinical-stage biotechs have no product sales, so that willingness matters more to them than to most industries.

For scale, $1 trillion is roughly 300 times the $3.28 billion in cash that Incyte, a large cancer and inflammation drugmaker, held at the end of the third quarter of 2026.2 That comparison is our own arithmetic, shown so readers can judge the size of the swing.

A solid balance sheet, measured

Incyte's cash is the best-checked number in this story. Its SEC filings put cash at $3.46 billion in the first quarter of 2026, $3.98 billion in the second and $3.28 billion in the third.2 At the end of fiscal 2025 it was $3.10 billion.2 The long view is more striking. Cash was $987 million in the second quarter of 2024 and $1.30 billion in the third quarter of 2024, so the company's reserves are roughly three times what they were two years ago.2

Incyte's cost of revenue tells a similar story of growth. It was $254.99 million in fiscal 2023, $312.07 million in 2024 and $372.13 million in 2025.2 Capital expenditure was $48.7 million in both fiscal 2024 and fiscal 2025, which suggests spending on pipeline work rather than heavy building.2 In the entity data we track, Incyte is also developing a treatment for PD-1 resistant head and neck cancer.2

We cannot say from this data why cash fell in the latest quarter. The filings give the balance, not the reason. The right reading is that this is a well-funded company, not one that depends on a hot market.

The clinical evidence that did arrive

The strongest data in the dossier came from Vor Bio. It announced final two-year results from the Phase 3 TELIGAN trial of telitacicept in IgA nephropathy, a kidney disease. Kidney function in treated patients declined by 0.6 mL/min/1.73 m² a year, against 5.7 for placebo. That is a difference of 5.1 (p<0.001).3 The company also reported reductions of 89% and 81% in the risk of confirmed kidney function declines of at least 30% and at least 40%.3 These are the company's own figures from a press release. They are not yet independently reviewed in our data.

Scribe Therapeutics reported third quarter results on 12 November. It is enrolling a first-in-human Phase 1 trial of STX-1150, an epigenetic silencing therapy for LDL cholesterol, with first data expected in the first half of 2027.4 Scribe says 50% to 70% of patients stop current LDL-lowering therapies within a year.4 It also says people with naturally occurring PCSK9 loss-of-function variants have 28% lower mean LDL-C and up to 88% lower coronary heart disease risk. STX-1150 aims to mimic that protection and could move cholesterol care from chronic treatment toward long-term prevention.4 That is a stated goal, not a result. No patient data exists yet.

Akari Therapeutics, which develops antibody drug conjugates (cancer drugs that deliver a toxic payload to tumour cells), said ADC-refractory patients are a growing unmet need. It called them an exclusive opportunity for its novel payload, which it says current and most future ADCs will not be able to access.5 Its lead programme, AKTX-101, is planned to enter Phase 1 in mid-2027.5 That is a long runway for a company that will need funding to reach it.

Where AI enters, and where claims need care

Radical Numerics said AI-designed viruses have treated its first patient, with an experimental treatment aimed at drug-resistant E. coli.6 That is the company's own claim, relayed in a newsletter. We have no outcome data behind it.

Reliability matters here, and our measurements show it. MIT Technology Review's newsletter items in our system have held up on only 6% of 16 checked claims.6 A separate MIT Technology Review piece covered Generation Lab, whose fact sheet says its treatment "blocks the systemic spread of aging in the bloodstream, reawakens the body's own repair mechanism and restores health and youth to multiple tissues".7 The author framed it as a startup's claim, and its source also scores 6% on our checks. We treat it as marketing language, not evidence. The wire-service releases behind the Scribe, Vor, Akari and BioArctic items score 54% across 6,752 checked claims. That is better, but still means roughly half of claims from such releases do not hold up, so the figures above are company statements until confirmed.

The commercial side is steadier

Not every biotech depends on financing markets. BioArctic's royalty on Leqembi, the Alzheimer's drug sold by its partner Eisai, was SEK 179 million in the second quarter of 2026, up about 10 percent on the same quarter of 2025.8 The company noted that the 2025 quarter included a one-time stockpiling effect in China of around JPY 5.3 billion. Excluding it, royalty revenues grew approximately 43 percent year over year.8 Global Leqembi sales in the quarter were JPY 29.3 billion.8 The comparison is distorted, so the 43 percent figure is the fairer measure of underlying growth.

The dossier's narrative also mentions strong demand for Eli Lilly's weight-loss drugs. The one source we hold on Lilly, a Motley Fool comparison with AbbVie, has held up on only 31% of 58 checked claims.9 We therefore do not rely on it.

The risk-off backdrop

The wider market gave several signals that investors were pulling back. OpenAI cut its funding target by $10 billion on 31 October.10 On 1 November, users withdrew $3.6 billion from the crypto exchange Binance when it reopened after a hack.11 None of these events involves biotech directly. Via News's analysis is that they matter because the same investors fund both AI and early-stage drug developers. When money tightens for one, the other tends to feel it. This is our reading, not a measured effect, and the dossier contains no data on biotech fundraising during these days.

What to watch

  • Scribe's first STX-1150 clinical data, due in the first half of 2027.4
  • Incyte's next quarterly cash balance, to see whether the latest drop continues.2
  • Whether Leqembi royalties keep growing once the China stockpiling comparison drops out.8
  • Akari's move into Phase 1 in mid-2027, and how it is funded.5

The honest summary is this. The science is advancing, and the best-capitalised companies are comfortable. Smaller developers with first data still ahead are the ones most exposed if the market's caution lasts.

Source documents

Via News is a conduit. We point to the source documents behind this report: we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score12 source documents12 with a live linkVerifiability: Strong
  1. [1]News articleMotley Fool
    AbbVie vs. Eli Lilly: Which Star Pharma Stock Is a Better Buy in 2026?
  2. [2]News articleYahoo Finance· October 15, 2026
    Akari Therapeutics CEO Highlights Differentiated ADC Payload Strategy and Path Toward Clinical Development in New CEO Corner
  3. [3]News articleMIT Technology Review
    A startup claims it’s found a drug to make your blood young
  4. [4]News articleYahoo Finance· July 27, 2026
    OPKO Health Reports Second Quarter 2026 Business Highlights and Financial Results
  5. [5]News articleYahoo Finance· July 29, 2026
    Sales of Leqembi® totaled 29.3 billion yen in the second quarter 2026
  6. [6]News articleYahoo Finance· November 12, 2026
    Scribe Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
  7. [7]News articleYahoo Finance· October 22, 2026
    Telitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA Nephropathy
  8. [8]News articleMIT Technology Review
    The Download: AI’s trillion-dollar gamble and OpenAI’s biology data bid
  9. [9]News articleMIT Technology Review
    The Download: a secretive antiaging drug and joining virtual power plants
  10. [10]News articleMIT Technology Review
    The Download: computing’s next leap and permafrost’s climate threat
  11. [11]Press releaseGlobeNewswire· July 15, 2026
    Three Biotechs Deliver Catalysts to Watch
  12. [12]News articleNasdaq· July 29, 2026
    Top Biotech Gainers: KNSA Soars On Q2 Results, TRIB, OPK On Watch, MPLT On The Mend?

Are you or your business in this article?

If something is wrong, out of context or missing, tell us. We correct errors with a dated note, and people named in an article can publish their response under it.

Correct, add context or respond →

Not a source? Spotted an error? Report an error

How this story was made

Spotted an error? Use “Correct this article” (bottom right), or select any sentence, to report it or respond to that point.

  1. Built from 12 source documents from 5 publications, dated 15 Jul 2026 to 12 Nov 2026
  2. Published 19 Nov 2026
  3. No responses yet from the people or organisations in this story. Are you in this story? Respond on the record ›
  4. Part of the Via News record, fingerprinted daily so it cannot be quietly rewritten. What that means › · Report an error ›
Via News Editorial Team

The Via News Editorial Team writes analysis and news from the Via News source-traceability system, under the editorial responsibility of L. Miguel Salvado, Editor. Each article is built only from source documents we hold and lists them at the end, so every claim can be checked. Articles generated with AI say so under the byline, as the EU AI Act requires.